Sionna Therapeutics Cuts 46% of Staff in CF Pipeline Restructuring
NewsData.io · United States · Nov 10, 2026
Sionna Therapeutics (NASDAQ: SION) eliminated approximately 46% of its workforce in September as part of a strategic pivot to focus exclusively on a single cystic fibrosis drug pair, SION-451 and galicaftor. The company disclosed the cuts in its third-quarter earnings report on November 10, also announcing it would halt development of SION-719. The layoffs signal a significant reduction in headcount at this biotech firm, potentially freeing up specialized life-sciences talent in the candidate market.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
Sionna Therapeutics is laying off approximately 46% of its workforce — roughly 27 employees based on a year-start headcount of 59 — following the…
Detroit ABC affiliate WXYZ-TV (Channel 7) has eliminated at least 30 positions through a combination of buyouts and layoffs, according to sources who…
Dole Packaged Foods will permanently close its Atwater, California processing facility and a nearby Livingston laboratory, eliminating 404 jobs in…
About 1,400 IRS IT employees displaced by DOGE-directed downsizing have been reorganized into 'ONE IRS Readiness' teams with no defined mission…